Rhythm Pharmaceuticals
Boston, US · Founded 2013 · 494 employees on LinkedIn · 6 known investors
Rhythm Therapeutics develops precision medicines for rare neuroendocrine diseases, particularly those affecting the melanocortin-4 receptor pathway. The company's lead product, IMCIVREE (setmelanotide), is FDA-approved to treat severe obesity caused by genetic impairments in the hypothalamus.
Founders & leadership
KG
BH
Bart HendersoninPresident and Founder2008–2017
DM
David MeekerinPresident and Chief Executive OfficerPRESIDENT AND CHIEF EXECUTIVE OFFICER at KSQ Therapeutics
Board
ET
JS
NE
TF
Todd FoleyBoard director
CJ
Christophe JeanBoard director
DJ
David J. McGirrBoard director
DP
David P. Meeker, M.D.Board director
Investors · 6
Reported raises · per SEC filings
Form D private placements$60.5M disclosed across 2 rounds · 2015–2017
▶$20.5MraisedJan 2017 · 14 investors · PharmaceuticalsRule 506(b)
▶$20.5MraisedJan 2017 · 14 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- David P. Meeker, M.D.Director
- Neil ExterDirector
- David J. McGirrDirector
- Jonathan SilversteinDirector
- Edward T. MathersDirector
- Christophe JeanDirector
- Bart HendersonExecutive Officer, Promoter
- Todd FoleyDirector
- Keith GottesdienerExecutive Officer, Director, Promoter
- Offering amount
- $40.9M
- Amount sold
- $20.5M
- First sale
- Jan 2017
- Incorporated
- Corporation, Delaware, 2013
- Federal exemptions
- 06b
▶$40MraisedDec 2015 · 12 investors · PharmaceuticalsRule 506(b)
▶$40MraisedDec 2015 · 12 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Edward T. MathersDirector
- David J. McGirrDirector
- Jonathan SilversteinDirector
- Keith GottesdienerExecutive Officer, Director
- David P. Meeker, M.D.Director
- Neil ExterDirector
- Bart HendersonExecutive Officer
- Todd FoleyDirector
- Christophe JeanDirector
- Offering amount
- $40M
- Amount sold
- $40M
- First sale
- Aug 2015
- Incorporated
- Corporation, Delaware, 2013
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Founder mafia
2 people who came through Rhythm Pharmaceuticals went on to found or lead other companies.
In the news
How Investors Are Reacting To Rhythm Pharmaceuticals (RYTM) UK Orphan Expansion For IMCIVREE In Hypothalamic Obesity - Simply Wall St Newssimplywall.st · Aug 2026Frequently asked questions
- What does Rhythm Pharmaceuticals do?
- Rhythm Therapeutics develops precision medicines for rare neuroendocrine diseases, particularly those affecting the melanocortin-4 receptor pathway. The company's lead product, IMCIVREE (setmelanotide), is FDA-approved to treat severe obesity caused by genetic impairments in the hypothalamus.
- Who are Rhythm Pharmaceuticals's investors?
- Rhythm Pharmaceuticals's investors include Foresite Capital, HEALTHCARE ROYALTY PARTNERS, New Enterprise Associates (NEA), Pfizer Venture Investments, OrbiMed, Third Rock Ventures.
- How much funding has Rhythm Pharmaceuticals raised?
- Rhythm Pharmaceuticals has disclosed $60.5M raised across 2 rounds.
- Where is Rhythm Pharmaceuticals headquartered?
- Rhythm Pharmaceuticals is headquartered in Boston, US.